Cross-cohort analysis identified an immune checkpoint-based signature to predict the clinical outcomes of neuroblastoma.

Liang ZengHui XuShu-Hua LiShuo-Yu XuKai ChenLiang-Jun QinLei MiaoFang WangLing DengFeng-Hua WangLe LiSha FuNa LiuRan WangYing-Qing LiHai-Yun Wang

Published in: Journal for immunotherapy of cancer (2023)

We propose an ICS that significantly differentiates between low-risk and high-risk patients, which might add prognostic value to age and provide clues for immunotherapy in NB.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
data analysis